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Abstract
Objectives To examine the extent of multiplicity of data in trial reports
and to assess the impact of multiplicity on meta-analysis results.
Design Empirical study on a cohort of Cochrane systematic reviews.
Data sources All Cochrane systematic reviews published from issue 3
in 2006 to issue 2 in 2007 that presented a result as a standardised
mean difference (SMD). We retrieved trial reports contributing to the first
SMD result in each review, and downloaded review protocols. We used
these SMDs to identify a specific outcome for each meta-analysis from
its protocol.
Review methods Reviews were eligible if SMD results were based on
two to ten randomised trials and if protocols described the outcome. We
excluded reviews if they only presented results of subgroup analyses.
Based on review protocols and index outcomes, two observers
independently extracted the data necessary to calculate SMDs from the
original trial reports for any intervention group, time point, or outcome
measure compatible with the protocol. From the extracted data, we used
Monte Carlo simulations to calculate all possible SMDs for every
meta-analysis.
Results We identified 19 eligible meta-analyses (including 83 trials).
Published review protocols often lacked information about which data
to choose. Twenty-four (29%) trials reported data for multiple intervention
groups, 30 (36%) reported data for multiple time points, and 29 (35%)
reported the index outcome measured on multiple scales. In 18
meta-analyses, we found multiplicity of data in at least one trial report;
the median difference between the smallest and largest SMD results
within a meta-analysis was 0.40 standard deviation units (range 0.04 to
0.91).
Conclusions Multiplicity of data can affect the findings of systematic
reviews and meta-analyses. To reduce the risk of bias, reviews and
meta-analyses should comply with prespecified protocols that clearly
identify time points, intervention groups, and scales of interest.
Introduction
Meta-analyses of randomised clinical trials are crucial for
making evidence based decisions. However, trial reports often
present the same data in multiple forms when reporting different
intervention groups, time points, and outcome measures.1
Although this multiplicity has always been a challenge in
meta-analyses, its potential as a source of bias has received little
attention.
The choice of the outcome of interest to include in systematic
reviews is generally based on clinical judgment. However, since
a fundamentally similar outcomemight bemeasured on different
scales, standardisation to a common scale is therefore required
before the outcome can be combined in the meta-analysis. This
standardisation is typically achieved by calculating the
standardised mean difference (SMD) for each trial, which is the
difference in means between the two groups, divided by the
pooled standard deviation of the measurements.2 By this
transformation, the outcome becomes dimensionless and the
scales are comparable, because the results are expressed in
standard deviation units. For example, a meta-analysis
addressing pain might include trials measuring pain on a visual
analogue scale and trials using a five point numerical rating
scale. Combining these outcomes on different scales potentially
adds a layer of multiplicity, because the outcome of interest
might be measured onmore than one scale not only across trials
but also within the same trial. Multiplicity of data in trial reports
might lead to biased decisions about which data to include in
meta-analyses and hence threaten the validity of their results.
In this study, we empirically assessed whether selecting between
multiple time points, scales, and treatment groups affected SMD
results in a randomly selected sample of Cochrane reviews.
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Methods
Data source and selection
We included all Cochrane systematic reviews published in the
Cochrane Library over 1 year (between issue 3 in 2006 and
issue 2 in 2007) that presented a result as an SMD. For every
review, we retrieved reports of all randomised trials that
contributed to the first SMD result, and downloaded the latest
protocols for all reviews in June 2007. Reviews were eligible
if the SMD result was based on two to ten randomised trials
and if the review protocol described the outcome. We excluded
reviews if they only presented results of subgroup analyses.
We defined the index SMD result as the first pooled SMD result
presented in the abstract or in the main body of text of the review
that was not based on a subgroup analysis. We used index SMD
results to identify a specific outcome for each meta-analysis
from its protocol. To ensure that the review authors had not
received additional outcome data from the authors of relevant
trials, we only considered the first SMD result that was based
exclusively on published data.
Based on the published protocol of each review, two observers
(BT, EN) independently extracted all data from the original trial
reports that could be used to calculate the SMD for the outcome
that met our inclusion criteria. From each trial report, we
extracted data for all experimental or control groups, time points,
and measurement scales, provided that they were compatible
with the definitions in the review protocol. If any required data
were unavailable, we made approximations as previously
described.3We did not include interim analyses. Disagreements
were resolved by discussion. We did not contact trial authors
for unpublished data. Selection of reviews and trials and the
extraction of data from trial reports were prespecified (protocol
available on request).
Review methods
We used Monte Carlo simulations to determine the variation in
meta-analysis results from different SMD estimates, calculated
frommultiple time points, intervention groups, andmeasurement
scales. We also used this simulation to estimate the overall
impact of multiplicity. During each simulation, we randomly
sampled one SMD and the corresponding standard error for
each component trial in a specific meta-analysis. We used
sampling with replacement from the population of all possible
SMDs caused by multiplicity, and selected one SMD per trial.
We then used this randomly sampled SMD and the
corresponding standard error for fixed or random effects
meta-analysis (as originally done in the published reviews), and
calculated a pooled SMD for each meta-analysis. We repeated
this process 10 000 times—that is, we undertook each
meta-analysis 10 000 times, with a random selection of one
SMD per trial each time. We then examined the distribution of
pooled SMDs in histograms.
To estimate the impact of a single source of multiplicity
(intervention groups, time points, measurement scales), we
allowed only one source of multiplicity to vary at a time when
randomly sampling SMDs for each trial. We standardised the
other sources of multiplicity at prespecified standard values
(group: pooled groups, time point: post treatment values, scale:
first scale mentioned in text). For example, the analysis of
multiplicity from different scales was based on post treatment
values and pooled groups (if there were several possible groups).
We would then randomly sample the values of the different
scales for this time point and these groups to calculate the pooled
SMD results. We expressed the variability of SMD results due
to multiplicity as the difference between the smallest and largest
pooled SMD results obtained from theMonte Carlo simulations.
Onlymeta-analyses including trials withmultiplicity contributed
to these analyses. Finally, we compared themedian pooled SMD
from the Monte Carlo simulations to the index SMD that was
published in the Cochrane review using a pairedWilcoxon test.
Results
Figure 1⇓ shows the flowchart for the selection ofmeta-analyses.
The 19 eligible meta-analyses included 83 trials that contributed
to our study.4-22 Table 1⇓ shows the characteristics of included
reviews, which addressed various condition types: psychiatric
(eight reviews), musculoskeletal (two), neurological (two),
gynaecological (one), hepatological (one), respiratory (one),
and other (four). We studied psychological interventions in 10
meta-analyses, pharmacological interventions in four, physical
interventions in three, and other interventions in two (exercise
and humidified air). The index outcomes analysed in the 19
meta-analyses were diverse: pain in three, another symptom in
13, and other outcomes in three.
Information in review protocols
Table 2⇓ shows the level of information given in the review
protocols. The protocols did not contain any information about
which scales should be preferred. Eight protocols gave
information about which time point or period to select, but only
one gave enough information to avoid multiplicity, because the
time point relevant for the selected index outcome was
post-treatment, meaning that the data were collected by the end
of treatment. A typical statement, which allowed for a potentially
biased choice regarding the selection of a time point, was: “All
outcomes were reported for the short term (up to 12 weeks),
medium term (13 to 26 weeks), and long term (more than 26
weeks).”7 Another review about humidified air for treating
croup15 stated: “The outcomes will be separately recorded for
the week following treatment.” The selected outcome in this
particular review was croup symptom score and none of the
three included trials ran for this length of time, but reported
symptoms 20 min to 12 hours after the intervention. Eighteen
protocols described which type of control group to select but
none reported any hierarchy among similar control groups or
any intention to combine such groups.
Furukawa and colleagues provided an example of a protocol
with many possible intervention or control groups.8 The authors
aimed to compare combined psychotherapy and
pharmacotherapywith psychotherapy or pharmacotherapy alone.
They defined psychotherapy broadly, as “any other
psychological approach.” 8 The pooled index SMD was based
on seven trials, three of which had more than one possible
intervention group.23-25 For three trials26-28 with only one
intervention group, each contained three groups that could be
used as control groups: one receiving pharmacotherapy only,
one receiving psychotherapy only, and one receiving
psychotherapy plus placebo.
Observed multiplicity in trial reports
Table 3⇓ presents the extent of multiplicity observed in the
eligible reviews. Table 4⇓ gives an example of multiple eligible
measurement scales, showing the different scales possible in
the meta-analysis by Hunot and colleagues.10
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Observed multiplicity in meta-analyses
In 11 (58%) meta-analyses, we identified at least one trial that
provided data for more than one intervention or control group.
Thirteen (68%) meta-analyses included at least one trial that
reported more than one eligible time point and 12 (63%)
included at least one trial that reported the index outcome using
more than one eligible measurement scale. We identified one
meta-analysis without multiplicity, because all three included
trials only reported data of one intervention and control group,
one eligible time point, and one measurement scale for the index
outcome.18
Effects ofmultiplicity onmeta-analysis results
Figure 2⇓ shows the distributions of possible pooled SMDs in
each meta-analysis, after we randomly selected one possible
SMD result per trial. Any type of multiplicity of data in the
included trials affected pooled SMD results in 17 (89%) of 19
meta-analyses. The remaining two meta-analyses were not
affected, because one study did not have multiple data in the
trial reports18 and the observed multiplicity in another had no
effect on the pooled SMD results.7 In one study, theMonte Carlo
distributions do not include the published SMD, because the
review authors used changes instead of end of follow-up values
to calculate the SMD.18
In all 11 (58%) meta-analyses including at least one trial with
more than one experimental or control group, we found
variability in the pooled SMD results due to this type of
multiplicity. In 12 (63%) meta-analyses, we found variability
in the pooled SMD results due to multiplicity of data regarding
time points (figure 2). In one meta-analysis with two trials that
reported more than one eligible time point, we did not find
multiplicity due to these different time points.7 In ten (53%)
meta-analyses, we found variability in pooled SMD results from
trial data of multiple measurement scales used for the index
outcome. In two meta-analyses, one trial in each meta-analysis
reported data for more than one measurement scale for the index
outcome, but this multiplicity did not affect the pooled SMD
results.6 22 In 12 (63%) reviews, the published pooled SMDs
were more favourable for the experimental intervention than
the median pooled SMD from the simulations (P=0.49).
Table 5⇓ presents the variability of pooled SMD results
according to different sources of multiplicity (that is, groups,
time points, or scales). Eighteen meta-analyses included trials
with multiple data for at least one source. In these 18
meta-analyses, the treatment effect from multiplicity of data
varied greatly (median difference between the smallest and
largest SMDs within the same meta-analysis, 0.40 standard
deviation units, range 0.04 to 0.91).
Discussion
In 18 of the 19meta-analyses in our study, we foundmultiplicity
of data in at least one trial report within each meta-analysis,
which frequently resulted in substantial variation in the pooled
SMD results. The impact of multiple data in trial reports
regarding intervention groups, time points, or measurement
scales on meta-analysis results varied greatly across
meta-analyses, ranging from almost no effect (0.04 standard
deviation units) to a substantial one (0.91 standard deviation
units, corresponding to a large treatment effect),29with a median
difference of 0.40 standard deviation units. We also estimated
the effect of the individual sources of multiplicity, holding the
other sources constant.
Example of potential implications of
multiplicity of data
Table 6⇓ provides an example of data from trials investigating
the effects of pharmacotherapy on anxiety levels. Depending
on which time point is examined, the effect of pharmacotherapy
varied widely from week to week within the individual trials.
When we randomly selected one time point for each trial, SMDs
varied from −0.76 (indicating a large benefit) to 0.05 (indicating
little effect). For example, in the Fineberg 2005 trial, there was
a large difference in the treatment effect from weeks 8 to 16.
If a meta-analysis were to pick only the most favourable trial
results, its result would be biased and overly optimistic, which
might affect clinical judgment about whether to use a particular
treatment. Therefore, if the protocol does not state any
prespecified time points for the meta-analyses, the meta-analysts
might make data driven decisions based on the trial results as
a whole. In the example in table 6, one could argue two
strategies: to include the latest time point from all trials, or to
use the length of the shortest trials and extract time points from
the other trials that match this time point best. Another solution
would be to include all time points in one analysis, similar to
an analysis of repetitive measures in an individual trial (see
below).
Strengths and limitations of study
Our selection of Cochrane reviews in this study was random,
and the variability of the SMD results did not seem related to
particular types of interventions or outcomes. To estimate the
impact of multiplicity on meta-analysis results, we randomly
selected one SMD per trial from a pool of eligible SMDs with
equal probability and used these to calculate pooled SMDs for
each meta-analysis. However, in practice, implicit rules
regarding data extraction might apply within specialties. For
example, one scale might be more commonly used than others,
for example, Hamilton’s depression scale. Such implicit
hierarchy of scales would be expected to reduce the multiplicity,
but should be made explicit in protocols for systematic reviews.
Our results are transparent because we only included published
results. Therefore, we probably underestimated the true level
of multiplicity, since selective reporting of outcomes in trials
is common.30-33 Positive, significant results are more likely to
be published than non-significant results.34 Alternatively, if our
random selection of SMDs for the meta-analyses did not reflect
how review authors typically select in practice, we might have
overestimated the observed effects of multiplicity.
Our study was possible because authors of Cochrane reviews
must publish their protocols before they undertake and publish
the review. We believe that most non-Cochrane meta-analyses
do not have available protocols,35 and therefore the scope for
multiplicity is probably greater than in Cochrane reviews.
Although we examined three common sources of multiplicity
of data in trial reports, there are other types of multiple data in
trial reports—for example, different types of analysis such as
intention to treat and per protocol analyses. Review authors
might also be influenced by how many and which outcomes to
select according to how favourable results appear to be in the
published trial reports. The effect of the selection of scales, time
points, and control groups has not been systematically assessed
in any of the published Cochrane reviews.
The extent of multiplicity of data identified in trial reports is a
function of the information provided in the review protocols:
we would expect a poorly specified outcome to increase
multiplicity. Data extraction for a meta-analysis depends on the
information given by trial reports, and therefore it cannot be
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fully specified in advance without knowledge of the included
trials. However, to minimise data driven selection of time points,
measurement scales, or intervention groups, researchers should
specify these decisions at the protocol stage. If amendments to
the protocol are indicated, they should be reported
transparently.36 37
Comparison with other studies
To our knowledge, our study is the first to show empirically the
extent to which multiplicity of data can compromise the
reliability of meta-analysis results. We have previously reported
results from an observer agreement study of ten meta-analyses
included in the present study.2 We found that disagreements in
observers were common and often large, mainly because of: the
different choices of groups, time points, scales, and calculations;
different decisions on the inclusion or exclusion of particular
trials; and data extraction errors.2Bender and colleagues describe
the problem of multiple comparisons in systematic reviews.1
They identified common reasons for multiplicity in reviews,
but did not estimate the impact on the meta-analysis results.1 In
our study, we included meta-analyses of SMDs, which could
be associated with multiplicity of data because of the use of
different measurement scales in included trials. However,
multiplicity of data due to selection of time points and groups
is not unique to SMD results and could apply to other effect
measures, such as binary outcomes.
Possible approaches to minimise bias due to
multiplicity of data
One approach to dealing with multiplicity in systematic reviews
is to extract, analyse, and report all data available for
intervention groups, time points, and measurement scales.
However, this method could lead to considerable problems at
interpretation, in view of the potential discrepancies between
different scales or time points. As with the repetitive measures
in an individual trial, all available time points reported in
included trials could be analysed in a single meta-analysis while
fully accounting for the correlation of repetitive measurements
within a trial.38 Alternatively, assessments from different scales
measuring similar concepts could be analysed in a single
multivariate model, similar to the use of bivariate models in
diagnostic research.39 Although the first approach of including
repetitive assessments in a single analysis could be easily
understandable, many readers could find the second approach
difficult to understand.
Another approach could be to provide detailed protocols for
systematic reviews with clearly specified time points, scales,
and groups. Protocols should also include explicit and
transparent hierarchies of each source of data, or strategies to
combine sources (for example, if there are several control
groups). Clinical judgment will be important here. Ideally, the
choice of time points and scales should be evidence based, but
empirical evidence for the most interesting time points and a
hierarchy of scales according to their validity and responsiveness
are rarely available. In addition, it is difficult to foresee
everything at the protocol stage, and the scope, methodological
quality, and quality of reporting of included studies might
require subsequent modifications.40 Only Cochrane reviews are
formally required to have a published protocol; however, and
only about 10% of non-Cochrane reviews explicitly state a
formal protocol.37 Protocol amendments could affect the results
and conclusions of systematic reviews and should be made only
after careful consideration and be reported transparently.36 37
Furthermore, the reporting of the methods and the results in
meta-analyses must clearly explain how the results were
achieved and how any multiplicity of data was handled.36
Conclusions
Multiplicity of data in trial reports and review protocols lacking
a detailed specification of eligible time points, scales, and
treatment groups can lead to substantial variability in
meta-analysis results. Authors of systematic reviews should
anticipate and consider the multiplicity of data in trial reports
when writing protocols. To enhance reliability of meta-analyses,
protocols should clearly define time points to be extracted,
provide a hierarchy of scales, clearly define eligible treatment
and control groups, and present strategies for handling
multiplicity of data.
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Tables
Table 1| Characteristics of included systematic reviews
GroupInterventionConditionOutcomeAuthor
Cochrane Injuries GroupViolence prevention programmeAggression/violenceSchool responsesMytton et al16
Cochrane Pregnancy and Childbirth GroupEpiduralCaesarean sectionNeonatal neurological and
adaptive score
Afolabi et al5
Cochrane Depression, Anxiety, and
Neurosis Group
Behavioural therapy or cognitive
behavioural therapy
Obsessive compulsive disorderDepressionO’Kearney et al17
Cochrane Schizophrenia GroupSupportive therapySchizophreniaGeneral functioning scoreBuckley and Pettit7
Cochrane Depression, Anxiety, and
Neurosis Group
PsychotherapyCommon mental disordersAnxiety/depressionAbbass et al4
Cochrane Hepato-Biliary GroupBile acidsNon-alcoholic fatty liver
disease
Radiological responseOrlando et al18
Cochrane Consumers and Communication
Group
Telephone follow-upPost discharge problemPatient disease knowledge or
symptom management
Mistaen and Poot14
Cochrane Acute Respiratory Infections
Group
Humidified airCroupSymptom scoreMoore and Little15
Cochrane Back GroupLow level laser treatmentLow back painLow back related disabilityYousefi-Nooraie et al22
Cochrane Back GroupAcupunctureNeck disorderPainTrinh et al19
Cochrane Ear, Nose, and Throat Disorders
Group
Cognitive behavioural therapyTinnitusSubjective tinnitus loudnessMartinez Devesa et al13
Cochrane Menstrual Disorders and
Subfertility Group
AnalgesicHysterosalpingography (tubal
patency)
PainAhmad et al6
Cochrane Stroke GroupEMG biofeedbackStrokeRange of movementWoodford and Price21
Cochrane Depression, Anxiety, and
Neurosis Group
ExerciseAnxietyAnxietyLarun et al12
Cochrane Depression, Anxiety, and
Neurosis Group
Psychological treatmentObsessive compulsive disorderSymptom levelGava et al9
Cochrane Depression, Anxiety, and
Neurosis Group
Combined treatment
(psychotherapy and
antidepressant)
Panic disordersGlobal judgmentFurukawa et al8
Cochrane Depression, Anxiety, and
Neurosis Group
Pharmacotherapeutic
augmentation
Treatment-resistant anxiety
disorders
Symptom severity scaleIpser et al11
Cochrane Pain, Palliative and Supportive
Care Group
Psychological interventionsNeedle-related procedural pain
and distress
PainUman et al20
Cochrane Depression, Anxiety, and
Neurosis Group
Psychological therapiesGeneralised anxiety disorderWorry/fear symptomsHunot et al10
EMG=electromyography.
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Table 2| Content of the review protocols
Hierarchy of
measuring
Eligible measuring
methods or scales
Hierarchy of
time points
Eligible time
points
Hierarchy of
control groups
Eligible control
groups
Eligible
intervention
groups methods or
scales
–Yes–Yes–YesYesMytton et al16
–Yes––Yes*YesYesAfolabi et al5
–Yes–––YesYesO’Kearney et al17
–Yes–Yes–YesYesBuckley and Pettit7
–Yes–Yes–YesYesAbbass et al4
–Yes–––YesYesOrlando et al18
–Yes–Yes–YesYesMistaen and Poot14
–Yes–YesYes*YesYesMoore and Little15
–Yes–––YesYesYousefi-Nooraie et al22
–Yes–––YesYesTrinh et al19
–Yes–––YesYesMartinez Devesa et al13
–Yes–Yes–YesYesAhmad et al6
–Yes––––YesWoodford and Price21
–Yes–––YesYesLarun et al12
–Yes–––YesYesGava et al9
–Yes–Yes–YesYesFurukawa et al8
–Yes–––YesYesIpser et al11
–Yes–––YesYesUman et al20
–YesYesYes–YesYesHunot et al10
*Only one possible control group stated.
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Table 3| Observed multiplicity of data from trials in meta-analyses
No (%) of trials with multiplicity of data
Measurement scalesTime pointsIntervention groupsAny of the three sourcesNo of trials included
1 (50)01 (50)1 (50)2Mytton et al16
01 (50)01 (50)2Afolabi et al5
001 (501 (50)2O’Kearney et al17
02 (100)02 (100)2Buckley and Pettit7
2 (100)1 (50)02 (100)2Abbass et al4
00003Orlando et al18
001 (33)1 (33)3Mistaen and Poot14
02 (67)02 (67)3Moore and Little15
1 (33)1 (33)02 (67)3Yousefi-Nooraie et al22
1 (33)3 (100)03 (100)3Trinh et al19
1 (25)3 (75)3 (75)4 (100)4Martinez Devesa et al13
1 (20)2 (40)1 (20)3 (60)5Ahmad et al.6
3 (60)2 (40)2 (40)4 (80)5Woodford and Price21
2 (40)3 (60)1 (20)4 (80)5Larun et al12*
5 (71)3 (43)4 (57)6 (86)7Gava et al9
4 (57)2 (29)6 (86)6 (86)7Furukawa et al8
3 (43)5 (71)0 (0)6 (86)7Ipser et al11
002 (22)2 (22)9Uman et al20
5 (56)02 (22)5 (56)9Hunot et al10
29 (35)30 (36)24 (29)55 (66)83All reviews
*One trial was excluded because of lack of data in the trial reports.
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Table 4| Possible measurement scales to include in the meta-analysis by Hunot and colleagues10
ScaleTrial
Penn state worry questionnaire
Worry scale
Akkerman 2001
Worry scale
Percentage of an average day during past month that patient reported worrying
Fear questionnaire
Barlow 1992
Penn state worry questionnaireDugas 2003
Penn state worry questionnaire
Worry and anxiety questionnaire (only six GAD somatic symptom items included)
Ladouceur 2000
Worry composite: standardised combined scores on Penn state worry questionnaire and Spielberger state-trait anxiety inventory scalesMohlman 2003a
Anxiety and worry composite: standardised combined scores on Beck anxiety inventory, symptom checklist anxiety, and Penn state worry
questionnaire scales
Mohlman 2003b
Penn state worry questionnaireStanley 2003
Percentage of an average day during past month that patient reported worrying (question in ADIS-IV (DiNarelo 1994))
Penn state worry questionnaire
Wetherell 2003
Fear thermometer (assessment of overall subjective anxiety on 20 cm unmarked scale which patients marked to show anxiety in the past week
overall)
Fear survey schedule intensity subscale
Fear survey schedule severity subscale
Woodward 1980
GAD=generalised anxiety disorder.
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Table 5| Variability in meta-analyses results
SMD range within the same meta-analysis (median, range)No (%) of meta-analyses with multiplicity of data (n=19)Source of multiplicity
0.09 (0.01 to 0.43)11 (58)Intervention groups
0.19 (0.03 to 0.82)13 (68)Time points
0.23 (0.01 to 0.45)12 (63)Measurement scales
0.40 (0.04 to 0.91)18 (95)Any source
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Table 6| Potential implications of multiple time points on treatment effect in a meta-analysis11
McDougle 2000Hollander 2003Fineberg 2005Erzegovesi 2004Denys 2004Carey 2005Atamaca 2002
Timepoint
(weeks)
0.44 (−0.25 to 1.14)––––––1
0.10 (−0.59 to 0.78)––––−0.27 (−0.89 to
0.34)
−0.03 (−0.79 to 0.73)2
−0.30 (−0.99 to 0.39)––––––3
−0.02 (−0.70 to 0.67)–−0.17 (−1.03 to 0.69)––−0.15 (−0.76 to
0.47)
−0.40 (−1.16 to 0.37)4
−0.66 (−1.36 to 0.05)––––––5
−0.92 (−1.65 to −0.20)––––−0.27 (−0.89 to
0.34)
−0.90 (−1.69 to −0.10)6
–−0.61 (−1.65 to
0.42)
0.12 (−0.74 to 0.98)–−0.82 (−1.47 to
−0.18)
–−2.12 (−3.08 to −1.17)8
––−0.15 (−1.01 to 0.71)––––12
–––−0.52 (−1.41 to
0.38)
–––15
––−0.27 (−1.13 to 0.59)––––16
–––−1.64 (−2.66 to
−0.61)
–––18
Data are standardised mean difference (95% CI).
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Figures
Fig 1 Flowchart for selection of meta-analyses
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Fig 2 Monte Carlo distributions of possible pooled SMDs in each meta-analysis. Dots=number of trials included. Open
dots=trials without multiplicity of data. Filled dots=trials with multiplicity of data. Stars=published pooled SMDs. Meta-analyses
are ordered according to the number of trials included. Negative SMDs on y axis indicate experimental intervention has
more beneficial effect than control intervention
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